Yellon DM - Search Results

1

From Protecting the Heart to Improving Athletic Performance - the Benefits of Local and Remote Ischaemic Preconditioning.

Sharma V, Marsh R, Cunniffe B, Cardinale M, Yellon DM, Davidson SM. Sharma V, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2015 Dec;29(6):573-588. doi: 10.1007/s10557-015-6621-6. Cardiovasc Drugs Ther. 2015. PMID: 26477661 Free PMC article. Review.

2

Limitation of myocardial reperfusion injury by AMP579, an adenosine A1/A2A receptor agonist: role of A2A receptor and Erk1/2.

Kis A, Baxter GF, Yellon DM. Kis A, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):415-25. doi: 10.1023/b:card.0000015856.02691.fa. Cardiovasc Drugs Ther. 2003. PMID: 15107596

3

Myocardial protection from either ischaemic preconditioning or nicorandil is not blocked by gliclazide.

Maddock HL, Siedlecka SM, Yellon DM. Maddock HL, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2004 Mar;18(2):113-9. doi: 10.1023/B:CARD.0000029028.75316.5e. Cardiovasc Drugs Ther. 2004. PMID: 15162072

4

Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.

Bose AK, Mocanu MM, Carr RD, Yellon DM. Bose AK, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2005 Jan;19(1):9-11. doi: 10.1007/s10557-005-6892-4. Cardiovasc Drugs Ther. 2005. PMID: 15883751 No abstract available.

5

The role of nitric oxide in mitochondria. Focus on "Modulation of mitochondrial Ca2+ by nitric oxide in cultured bovine vascular endothelial cells".

Davidson SM, Yellon DM. Davidson SM, et al. Among authors: yellon dm. Am J Physiol Cell Physiol. 2005 Oct;289(4):C775-7. doi: 10.1152/ajpcell.00277.2005. Am J Physiol Cell Physiol. 2005. PMID: 16157689 Free article. No abstract available.

6

Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection.

Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Davidson SM, et al. Among authors: yellon dm. Int J Biochem Cell Biol. 2006 Mar;38(3):414-9. doi: 10.1016/j.biocel.2005.09.017. Epub 2005 Oct 21. Int J Biochem Cell Biol. 2006. PMID: 16280253

7

Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro.

Bullard AJ, Yellon DM. Bullard AJ, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2005 Oct;19(5):333-6. doi: 10.1007/s10557-005-4595-5. Cardiovasc Drugs Ther. 2005. PMID: 16382295

8

Survival kinases in ischemic preconditioning and postconditioning.

Hausenloy DJ, Yellon DM. Hausenloy DJ, et al. Among authors: yellon dm. Cardiovasc Res. 2006 May 1;70(2):240-53. doi: 10.1016/j.cardiores.2006.01.017. Epub 2006 Mar 20. Cardiovasc Res. 2006. PMID: 16545352 Review.

9

Does hyperglycemia reduce proliferation or increase apoptosis?

Davidson SM, Yellon DM. Davidson SM, et al. Among authors: yellon dm. Am J Physiol Heart Circ Physiol. 2006 Sep;291(3):H1486; author reply H1487. doi: 10.1152/ajpheart.00301.2006. Epub 2006 Apr 14. Am J Physiol Heart Circ Physiol. 2006. PMID: 16617134 Free article. No abstract available.

10

A potential role for PTEN in the diabetic heart.

Mocanu MM, Field DC, Yellon DM. Mocanu MM, et al. Among authors: yellon dm. Cardiovasc Drugs Ther. 2006 Aug;20(4):319-21. doi: 10.1007/s10557-006-8876-4. Cardiovasc Drugs Ther. 2006. PMID: 16779530 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

478 results

Search Page